Phase I and Phase II trials evaluate safety of allogeneic stem cells in Parkinson's disease, suggesting potential therapeutic benefits.
To evaluate the safety of intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cells (allo-hMSCs) in Parkinson’s disease (PD) across Phase I and Phase II clinical trials.
No takes yet. Share an insight, caveat, or question.
Onuigbo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: